Genticel to continue per protocol its phase II study with ProCervix after review by DSMB

Thursday, January 29, 2015

Genticel, a French biotechnology company and developer of therapeutic vaccines, has announced that the Data and Safety Monitoring Board (DSMB), an independent committee of experts which monitors safety data every six months during a study, met as scheduled on Jan. 22. It recommended the RHEIA-VAC study proceed without any modifications. The DSMB already had made the same recommendation during the first review on July 1, 2014.

[Read More]

Genticel completes recruitment for phase Ib HPV vaccine trial

Wednesday, March 7, 2012

Genticel, a biopharmaceutical company based in Toulouse and Paris, France, has completed the recruitment of all patients participating in its phase Ib clinical trial evaluating a lyophilized formulation of ProCervix, its candidate therapeutic HPV vaccine, on adult women already infected with human papillomavirus (HPV) genotypes 16 or 18.

[Read More]